Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (421-430 of 583) with videos related to

Pageof 59
Sort By:
Leukemia|March 25, 2017
No evidence for microsatellite instability in acute myeloid leukemiaC J Walker, A-K Eisfeld, L K Genutis, et al.
Blood|November 15, 1993
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583H Ozer, S L George, C A Schiffer, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Leukemia|August 30, 2019
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Cancer|March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Leukemia|July 4, 2015
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemiaR Sood, N F Hansen, F X Donovan, et al.
Blood|March 19, 2005
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapySusan P Whitman, Shujun Liu, Tamara Vukosavljevic, et al.
Pageof 59

Showing results (421-430 of 583) with videos related to

Sort By:
Pageof 59
Leukemia|March 25, 2017
No evidence for microsatellite instability in acute myeloid leukemiaC J Walker, A-K Eisfeld, L K Genutis, et al.
Blood|November 15, 1993
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583H Ozer, S L George, C A Schiffer, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Leukemia|August 30, 2019
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21Bhavana Bhatnagar, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Annals of Hematology|May 6, 2004
G3139, a BCL-2 antisense oligo-nucleotide, in AMLG Marcucci, W Stock, G Dai, et al.
Cancer|March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Cancer Cell|November 16, 2005
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinPaolo Neviani, Ramasamy Santhanam, Rossana Trotta, et al.
Leukemia|July 4, 2015
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemiaR Sood, N F Hansen, F X Donovan, et al.
Blood|March 19, 2005
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapySusan P Whitman, Shujun Liu, Tamara Vukosavljevic, et al.
Pageof 59